0000950170-24-027304.txt : 20240306
0000950170-24-027304.hdr.sgml : 20240306
20240306170615
ACCESSION NUMBER: 0000950170-24-027304
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240305
FILED AS OF DATE: 20240306
DATE AS OF CHANGE: 20240306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WINDSOR JAMES BRIAN
CENTRAL INDEX KEY: 0001790933
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38130
FILM NUMBER: 24726898
MAIL ADDRESS:
STREET 1: 2600 VIA FORTUNA, SUITE 360
CITY: AUSTIN
STATE: TX
ZIP: 78746
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC
CENTRAL INDEX KEY: 0001420565
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 134196017
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 738 MAIN STREET
STREET 2: UNIT 398
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-995-0900
MAIL ADDRESS:
STREET 1: 738 MAIN STREET
STREET 2: UNIT 398
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
ownership.xml
4
X0508
4
2024-03-05
0001420565
AILERON THERAPEUTICS INC
ALRN
0001790933
WINDSOR JAMES BRIAN
C/O AILERON THERAPEUTICS, INC.
738 MAIN STREET #398
WALTHAM
MA
02451
false
true
false
false
President and COO
false
Common Stock
2024-03-05
4
M
false
2000
A
7122
D
Common Stock
225
I
By son
Series X Non-Voting Convertible Preferred
2024-03-05
4
M
false
2
D
Common Stock
2000
0
D
On March 5, 2024, the Issuer's outstanding Series X Non-Voting Convertible Preferred Stock, par value $0.001 per share ("Series X Preferred Stock") automatically converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"), subject to certain beneficial ownership limitations. By operation of the certificate of designation for the Series X Preferred Stock, each share of Series X Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.
The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
/s/ James Brian Windsor
2024-03-06